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INTRODUCTION 
Last year, the US. Government's budget for Medical and Health expense was 
213.2 billion dollars. This year, it is estimated at 237.5 billion dollars.1 As a 
result, health-care reform, budget cuts and alternatives to primary medical care 
have become important issues among legislators and health care providers. 
Similarly, the focus of optometry's effort to resolve the increasing US. 
government Medicare costs has been to expand our role as primary health care 
providers. This expanded role in an optometric practice allows utilization of 
therapeutic pharmaceutical agents in the treatment of ocular disease. 
Therapeutic pharmaceutical drug legislation authorizes an optometrist to treat 
and manage ocular disease conditions that were previously referred to 
ophthalmologists. Allowing optometrists to treat conditions that they currently 
diagnose has proven to be cost effective by reducing unnecessary travel, 
especially in rural areas, and providing a competitive health service to prevent 
rising medical costs by eliminating the expense of an additional visit to a 
physician.2.4 Supporting evidence was demonstrated in a two-year study 
conducted by Paul Elwood, a leader of health maintenance organizations. From 
the study, it was concluded that if an optometrist practiced to the fullest extent of 
his training savings in health care costs up to 36% would be realized. 4 In 
addition to lowering costs, TPA legislation serves to provide accessible and 
available eye health and vision care that is efficacious as well as efficient. 
Optometry has provided effective and safe primary care utilizing therapeutic 
pharmaceutical drug agents for the past 18 years. The low incidence of 
malpractice suits provides the evidence to support this statement. As an 
example, during 18 years of TPA utilization there have been but four TPA 
malpractice suits in the entire nation.3 Because of the low incidence of 
malpractice suits, insurance rates have remained low. 8 
Furthermore, a study is ongoing in Wisconsin by the Bureau of Health Service 
Professions. They have reported on the use of therapeutic pharmaceutical 
agents on 11 ,977 administrations by 312 TPA certified optometrists in Wisconsin. 
According to this study, of the treated cases, 65% resulted in "condition resolved" 
7 
and 16% in condition "successfully treated" outcomes. Ten percent resulted in 
"risk minimized" and 6% in "condition stabilized." One percent were referred to 
"other health care providers." This study reported a low number of nine 
adverse reactions out of nearly 12,000 administrations. All nine cases were 
allergic reactions which resolved upon discontinuation of the medication. This 
study provides further evidence that TPA utilization is an effective and efficient 
alternative providing primary medical care at lower costs. 
However, despite benefits of low cost and effective care, optometry's legislative 
efforts to expand this role as primary health care providers has faced strong 
opposition. At the time of this report, 32 states have passed TPA legislation. The 
remaining 18 states are in process or have rejected the bills put forth.? It is 
obvious that these remaining 18 states urgently need to pass TPA legislation. In 
order to pass these laws, optometry needs to increase legislative and public 
awareness on the benefits of primary eye care. Very few studies have been 
done on the benefits and effectiveness of TPA utilization. A recent study by 
Farmer9 on the impact of TPAs on optometric practice in the Pacific Northwest 
was done to provide evidence of perceived benefits of TPA utilization. 
To date, there is very little to no information on the standard of care, and 
utilization of therapeutic pharmaceutical agents by optometrists as a function of 
the nature of a practice. This current study was formulated to establish solid data 
illustrating the effectiveness of optometrists using TPAs in an actual practice 
setting in the state of Washington (3 years of TPA utilization). This information 
will prove helpful to increase legislative awareness as to the importance of 
therapeutics and their safety, if used correctly, and the available alternatives to 
primary health care. Furthermore, this information may help resolve issues in 
other states where legislation is still pending. 
PROJECT GOALS: To determine the utilization of therapeutic 
-SUBGOAL 1: 
pharmaceutical agents (TPA) by optometrists in the 
state of Washington. 
To determine the disease conditions that are 
being treated by optometrists and 
specific TPAs that are utilized. 
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* O b j e c t i v e  1 . 3 :  
* O b j e c t i v e  1 . 4 :  
* O b j e c t i v e  1 . 5 :  
* O b j e c t i v e  1 . 6 :  
* O b j e c t i v e  1 .  7 :  
- S U B G O A L  2 . 0 :  
* O b j e c t i v e  2 .  1 :  
* O b j e c t i v e  2 . 2 :  
* O b j e c t i v e  2 . 3 :  
T o  d e t e r m i n e  t h o s e  o c u l a r  c o n d i t i o n s  t h a t  a r e  
b e i n g  t r e a t e d .  
T o  d e t e r m i n e  t h e  s p e c i f i c  T P A s  t h a t  a r e  
c u r r e n t l y  b e i n g  u t i l i z e d .  
T o  d e t e r m i n e  t h e  s p e c i f i c  c a s e s  t h a t  a r e  n o t  
b e i n g  t r e a t e d  b u t  a r e  b e i n g  r e f e r r e d .  
T o  d e t e r m i n e  s p e c i f i c  c a s e s  t h a t  a r e  b e i n g  
t r e a t e d  b y  T P A s  a n d  a r e  n o t  r e f e r r e d .  
T o  d e t e r m i n e  s p e c i f i c  c a s e s  t h a t  a r e  b e i n g  
t r e a t e d  b y  T P A s  a n d  a r e  a l s o  r e f e r r e d .  
T o  d e t e r m i n e  s p e c i f i c  c a s e s  t h a t  a r e  b e i n g  c o -
m a n a g e d .  
T o  d e t e r m i n e  t h e  c a s e s  t h a t  c o u l d  b e  m a n a g e d  
b y  o p t o m e t r i s t s  w i t h  a  c h a n g e  i n  p r e s c r i b i n g  
p r i v i l e g e s .  
T o  d e t e r m i n e  i f  t h e  u t i l i z a t i o n  o f  T P A s  
d i f f e r s  a s  a  f u n c t i o n  o f  t h e  n a t u r e  o f  t h e  
p r a c t i c e .  
T o  d e t e r m i n e  i f  t h e  u t i l i z a t i o n  o f  T P A s  d i f f e r s  
a s  a  f u n c t i o n  o f  t h e  m o d e  o f  p r a c t i c e .  
T o  d e t e r m i n e  i f  t h e  u t i l i z a t i o n  o f  T P A s  d i f f e r s  
a s  a  f u n c t i o n  o f  t h e  s i z e  o f  t h e  c o m m u n i t y .  
T o  d e t e r m i n e  i f  t h e  u t i l i z a t i o n  o f  T P A s  d i f f e r s  
a s  a  f u n c t i o n  o f  t h e  i n c o m e  o f  t h e  o p t o m e t r i s t .  
( )  
*Objective 2.4: 
*Objective 2. 5 
To determine if the utilization of TPAs differs 
as a function of the available referral sources 
in the community. 
To determine if the utiliization of TPAs differs as a 
function of the number of years in optometric practice. 
ID 
METHODOLOGY: 
The data were gathered through a mail survey, sampling patient 
encounters during the entire month of November, 1992. Surveys were sent to 
practicing TPA certified optometrists throughout the state of Washington. The 
roster was obtained through the Washington Board of Optometry. A total of 543 
surveys were sent and 61 were returned, resulting in a response rate of 11%. 
Washington state was chosen because of the good response rate on previous 
studies, proximity, a similar socio-economic profile to Oregon, and TPA utilization 
of three years. This allows for a strong comparison and provides solid data to 
other states regarding the utilization of TPAs. A cover letter was enclosed with 
the survey to explain the purpose of the study and a return addressed prepaid 
envelope. To protect anonymity in the study, all return envelopes were opened 
by a third party with the data sheets alone being analyzed in the study. The 
survey consisted of two parts: 
1.) TPA utilization: type of drug, diagnosis, referred to 
whom, co-managed, increased patient care with increase 
in prescription privileges. 
2.) personal data: type of practice, population size, years of 
practice, number of hours, income, specialty, number of 
referral sources. 
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RESULTS: 
I. OBJECTIVE 1.1: TO DETERMINE THOSE OCULAR CONDITIONS 
THAT ARE BEING TREATED 
The following is a report on all ocular conditions that were managed and treated 
by optometrists during the entire month of November; 660 cases were reported. 
The respondents were asked to record all ocular disease diagnosis (ICDM code) 
for each disease case that they managed during the month of November. This 
question was asked to determine the incidence of ocular conditions being 
managed within Washington state. See Table 1 and Figure 1. 
TABLE 1 
ICDM DIAGNOSIS 0/o OF N= cases 
DISEASE 
POPUL. 
372 Conjunct., infect. 12.12% 80 
365.9 Glaucoma 9.24% 61 
372.14 Conjunct., allerg. 8.18% 54 
918.1 Abrasion 7.42% 49 
373.00 Blepharitis 5.91% 39 
364.00 Iritis, (uveitis) 4.24% 28 
370.40 Keratoconjunct. 3.48% 23 
v43.1 Pseudophakia 3.48% 23 
930.00 Foreign body 3.33% . 22 
370.20 Keratitis 3.18% 21 
366.9 Cataract 2.88% 19 
370.00 Ulcer 2.73% 18 
375.15 Dry Eye Syndrome 2.27% 15 
365.00 Glaucoma, suspect 1.97% 13 
373.12 Hordeolum, int. 1.97% 13 
379.00 Episcleritis 1.67% 11 
379.31 Aphakia 1.52% 10 
372.72 Subcong. hemorrhag. 1.21% 8 
362.01 Diabetic retinop. 1.21% 8 
362.50 Macular degen. 1.06% 7 
362.01 Ocular hypertension 1.06% 7 
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II. OBJECTIVE 1.2: TO DETERMINE THE SPECIFIC TPA'S THAT ARE 
CURRENTLY BEING UTILIZED 
The standard of care changes as new pharmaceutical agents and information on 
diseases are discovered. In this study, optometrists were asked to list the name 
·brand of each drug used for each disease case to establish a drug of first choice 
in a clinical setting. The following report is a list of TPAs that are currently being 
used and their frequency for each diagnosis. (See table 2) 
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TABLE 2: DRUGS UTILIZED 
Disease ICDM Drug Utilized N =cases 
Conjunct., infect. 372.00 1. Gentamicin 15 
2.Tobrex 11 
3. Erythromicin 8 
4. Bacitracin 4 
5. Maxitrol 4 
6. Genoptic 4 
7.Biepha~de . 3 
-
--
8. Sodium sylamyd 3 
1- - ·----
9. Garamycin 2 
10. Polysporin 2 
11. Polytrim 2 
12. Genoptic/Dexaceclin 1 
13. Cibroxin 1 
14. Naphcon A 1 
15. Hypotears 1 
16. Ciloxicin 1 
17. FML 1 
18. Tobrex, Celluvisc 1 
19. Predforte/Steroid 1 
20. Tolnex , 
21. Garamycin/ AK Poly bac 1 
22. GenUPolytracin 1 
Glaucoma 365.9 1. Betoptic 14 
2. Timoptic 13 
3. Betoptic S 7 
4. Betagan 6 
5. None 6 
6. Optipropranolol 4 
7. Pilocarpine 1 
8. Betagan/Propine 1 
9. Timoptic/PIIocarpine 1 
1 0. Betagan/Pilocarpine 1 
Conjunct., allerg. 372.14 1. Naphcon A 18 
2. FML 4 
3. Dexaceclin 4 
4. Blephamide 3 
5. Albalon 2 
6. Maxitrol 1 
7. Pred-mild 1 
8. Econopred plus 1 
9. Vasoclear A 1 
1 0. Albalon/Gent 1 
- -
11. Prednisolone acetate 1 
15 
TABLE 2: DRUGS UTILIZED 
12. de contact lenses 1 
13. Flarex 1 
14. Spectromycin 1 
15. Genoptic 1 
16. Polysporin 1 
17. Vascon A 1 
18. Predforte 1 
Abrasion 918.1 1. Tobrex 18 
2. Genoptic 4 
3. AK poly bac 3 
4. Tobrex!Homatropine 3 
5. Gentamicin 2 
6. Tobradex 1 
7. Polysporin 1 
8. Muro 128 1 
9. Erythromycin!Tobrex 1 
1 0. Polytrim 1 
11. lllotycin/Homatropine 1 
12. Cyclopentolate/Polysporin 1 
I--
13. Bacitracin 1 
14. Homatropine/Erythromycin 1 
15. Sulfacetamide 1 
-
Blepharitis 373.00 1. Bacitracin 14 
2. Polysporin 9 
3. Erythromycin 6 
t--
4. Neosporin 1 
1-
5. FML 1 
6. Ocuclenz!Lid scrubs 1 
-
7. Blephamide 1 
8. Dexaceclin 1 
9. Ciloxan!Tobradex 1 
10. Ciloxan/Oexaceclin 1 
11. Genoptic 1 
12. Dexaceclin/Polysporin 1 
13. Predforte 1 
Iritis 364.00 1 . Predforte . 8 
2. Econopred 4 
3. Maxrtrol 3 
4. Predforte/Cyclogel 2 
5. Prednisone 1 
6. Homatropine 1 
7. Cyclomydril 1 
i 8. lnflamase forte 1 
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TABLE 2: DRUGS UTILIZED 
9. FML 1 
10. Flarex 1 
11. Gent 1 
12. Tobrex/Predforte/homatroprine 
Pseudophakia 1 . Pred forte 6 
2.None 4 
3. Mydriacii/Neosyn 1 
4. FML forte 1 
5. Maxitrol 3 
6. Tobradex 2 
7. Tobrex 1 
8. FML 1 
Keratoconjunctivitis 370.40 1. Genta 6 
2. Tobradex 3 
3. Econopred 1 
4. Chibroxin 1 
5. Polytrim 1 
6. Genta/ Polytracin 1 
7. Neosporin 1 
8. Blephamide 1 
9. Ciloxan 1 
1 0. Neosporin/Bactracin 1 
11. Erythromicin/Cellufresh/Gent 1 
12. TobrexNasocon 1 
Foreign Body 930.00 1. Tobrex 7 
2. Gent 2 
3. Homatropine 1 
4. Erythro/Tobrex 1 
5.Gentamicin Sulfate 1 
6. Tobrex!Homatropine 1 
7. Polytracin 1 
-· 
8. Homatropine/Proparacaine 1 
-
9. Tobrex/Cyclopentolate/Ophthetic 1 
t---
10. Tobrex/Cyclopentolate 1 
11. Homatropine/Gent 1 
12.Erythromicin , 
I 1 
Keratitis 370.20 1. Maxitrol 5 
2. Polysporin 3 
~
3. Genoptic 3 
4. Tobradex I 2 
5. Gent I 2 
6. Dexaceclin/tobrex 2 
17 
TABLE 2: DRUGS UTILIZED 
7. Sulf 10% 1 
8. Muro 128/Cellufresh 1 
9. Tobrex 1 
10. FML 1 
Ulcer 370.00 1. Tobrex 4 
2. Ciloxan/Tobrex 3 
3. Ciloxan 2 
4. Chibroxin 2 
5. Maxitrol 1 
6. Polytrim 1 
7. Homatropine 1 
8. Gentamicin 1 
9. Cipoloxan 1 
1 0. T obradex 1 
11. Chibroxin/Polysporin 1 
Cataract 366.90 1. None 18 
2. Mydriacil 1 
Dry Eye 375.15 1.Ak tears renewed 3 
2. Hypotears 2 
3.Ak polybac/celluvisc 1 
4. Cellufresh/refresh pm 1 
5. Vitamin A/Lacrilube 1 
6. Cellufresh 1 
7. Tears plus 1 
8. Polysporin 1 
9. Genoptic/Hypotears 1 
1--
1 0. Lacrilube 1 
1-
11. Tears plus 1 
12. Pred mild/Cellufressh 1 
Glaucoma Suspect 365.00 1. None 7 
2. Timoptic 1 
3. Pilocarpine 1 
4. Levobunolol 1 
5. Levobunoloi/Propine 1 
6. Blephamide 1 
7.Pilo/Atropine/pred forte 1 
Hordeolum 373.12 1. Polysporin 3 
2. Gentamicin 2 
3. Ak trol 2 
4. Polysporin/Dexaceclin 2 
5. Ery1hromicin 1 
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TABLE 2: DRUGS UTILIZED 
6. Tobrex 1 
7. Blephamide 1 
8. Dexaceclin 1 
Episcleritis 379 1. FML 4 
2. Prednisone 2 
3. Pred mild 1 
-
4. Tears plus 1 
5. Econopred plus 1 
6. pred forte 1 
7. Maxitrol 1 
Aphakia 379.31 1. None 5 
2. FML forte 1 
-
3. Decadron/Ciloxan 1 
4. Maxitrol 1 
5. Econopred 1 
6. Cellufresh 
Subcong. hemorrhage 372.72 1. None 3 
2. Hypotears/hot compress 1 
3. Hypotears 1 
r--
4. Cellufresh 1 
5. Lubricant 1 
-
6. Eye wassh 1 
Diabetic Retinopathy 362.01 1. None 7 
2. Mydriacyi/Phenylephrine/Hcl 1 
Macular Degeneration 362.5 1. None 5 
2. Tropicamide 1 
3. Zinc 1 
lg 
Ill. OBJECTIVE 1.3: TO DETERMINE THE SPECIFIC CASES THAT ARE NOT 
BEING TREATED BUT ARE BEING REFERRED. 
This study included a survey of the specific disease cases being referred to 
ophthalmologists and sub-specialties. Optometrists were asked to report disease 
cases that were referred and not treated during the entire month of November. 
See table 3 and Figure 2. 
*Out of 660 cases, 73 were referred to ophthalmologists, and other sub-
specialities. This yields a percentage of 11.06% of the total ocular 
disease patients seen that were referred and not treated. 
*The greatest number of referrals (13) were patients with the diagnosis of 
Glaucoma. 
*Pseudophakia was a close second with 11 referrals. 
*There were 7 cataract patients referred. 
*Diabetic retinopathy ranked forth on the list with 6 patients. 
* There were 4 aphakia patients referred. 
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TABLE 3: CASES THAT ARE NOT BEING TREATED BUT ARE REFFERED 
Diseases N= cases I COM 
Glaucoma 13 365.9 
Cataract 7 366.9 
Diabetic retinop 6 362.01 
Aphakia 4 379.31 
Foreign body 3 930.00 
Conjuct., infect. 3 372.00 
Iritis (uveitis) 2 364.00 
Glaucoma, suspect 2 365.00 
Pterygium 2 372.40 
Macular degen. 2 362.50 
Conjuct., allerg. 2 372.14 
Pseudophakia 2 V43.1 
Keratitis 1 370.20 
Detachment (tear) 1 361.9 
Tear insufficiency 1 375.15 
Dystropy 1 371.50 
Laceration 1 871.4 
other ret. disorders 1 362.89 
Bullous Keratopath 1 371.23 
Central serous r. 1 362.41 
Entropion 1 374.01 
Cararact, sec. 1 366.50 
Epiphoria 1 375.20 
Nuclear sclerosis 1 366.16 
Foreign body in conj. sac 1 930.1 
Chalazion 1 373.2 
Neoplasm, benign 1 229.00 
After cataract obscuring vision 1 366.53 
Total 64 
21. 
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IV. OBJECTIVE 1.4: TO DETERMINE SPECIFIC CASES THAT ARE BEING 
TREATED WITH TPAs AND ARE NOT REFERRED. 
Respondents were asked to record the patients who were treated and not 
referred. There were a total of 528 cases that were treated and not referred. 
Thus, the percentage of cases treated independently by optometrists was 80%. 
This question was asked to determine the types of ocular diseases that 
optometrists are managing independently with TPAs. See table 4 and Figure 
3. 
*Conjuctivitis, infect. was the most frequent disease case managed by 
optometrists with of 73 cases seen. 
*Corneal abrasion had the second highest number reported with 49 
cases. 
*Conjuctivitis, allerg. was listed with 42 cases managed. 
*Blepharitis was fourth on the list with 39 cases managed. 
*Glaucoma was fifth in on the list with 31 cases managed. 
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TABLE 4: CASES TREATED AND NOT REFERRED 
Diagnosis N= cases !COM 
Conjunc., infect. 73 372.00 
Abrasion 49 918.10 
Conjunc., allerg. 42 372.14 
Blepharitis 39 373.00 
Glaucoma 31 365.90 
Keratoconj. 23 370.40 
Iritis 20 364.00 
Keratitis 20 370.20 
Foreign body 19 930.00 
Ulcer 17 370.00 
Dry Eye 14 375.15 
Hordeolum, int. 12 373.12 
Episcleritis 10 379.00 
Pseudophakia 7 V43.1 
Glaucoma Suspect 6 365.00 
Subconj. Hemorrhag. 4 372.72 
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V. OBJECTIVE 1.5: TO DETERMINE SPECIFIC CASES THAT ARE BEING 
TREATED BY TPAs AND ARE ALSO REFERRED .. 
In this study, respondents were asked to record the cases that were treated and 
referred. See table 5 and Figure 4 
*The total number of treated and referred was 45 out of 660 managed. 
This calculates to a percentage of 7%. This percentage was lower 
than those treated and not referred (80%) or co-managed ( 9.85% ), 
thus leading to a decrease in the amount of unnecessary referrals. 
*Pseudophakia was the most frequent disease treated and referred. 
*Glaucoma was the second most common disease treated and 
referred. 
TABLE 5 
DISEASE N:cases ICDM 
Pseudophakia 9 V43.1 
Glaucoma 7 365.90 
Aphakia 4 379.31 
Conjuct., allerg. 3 372.14 
Conjuct., infect. 3 372.00 
Dry eye 2 375.15 
Foreign body 2 930 
Iritis 2 364.00 
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VI. OBJECTIVE 1.6: TO DETERMINE SPECIFIC CASES THAT ARE BEING 
CO-MANAGED. 
Respondents were asked to report cases that were co-managed with 
ophthalmologists. The total cases that were co-managed were 65 out of 660 
ocular disease cases. This resulted in a percentage of 9.85%. See table 6 and 
Figure 5. 
*The greatest number of cases being co-managed is Glaucoma. It had 
an occurance of 26 cases out of 65. 
*40% of the cases being co-managed were glaucoma patients. 
*18% of the co-managed cases were pseudophakia patients. 
*There were seven patients with iritis that required co-management. 
*There were four corneal ulcer patients that required co-management. 
*There were four aphakia patients that required co-management. 
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TABLE 6 
DIAGNOSIS N=CASES I COM 
Glaucoma 26 365.9 
Pseudophakia 12 v43.1 
Iritis 7 364.00 
Ulcer 4 370.00 
Aphakia 4 379.31 
after cataract obscurring vision 2 366.53 
Conjuct., allerg. 2 372.14 
Ptosis 2 374.30 
Diabetic retinop. 2 362.01 
Hemorrhage, retinal 2 362.81 
Detachment, tear 2 361.90 
TOTAL 65 
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FIGURE 5: CASES THAT ARE BEING COMANAGED 
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OBJECTIVE 1.7: TO DETERMINE THE CASES THAT COULD BE MANAGED 
BY OPTOMETRISTS WITH A CHANGE IN PRESCRIBING PRIVILEGES. 
The following table and figure illustrate the number of ocular disease cases 
seen that could have been managed by optometrists with a change in 
prescribing privileges. Respondents were asked to record all cases being 
referred that could have been managed independently with a change in 
prescribing privileges. See Table 7 and Figure 6. 
*Glaucoma had the highest with 6 cases. 
*Conjuctivitis, infectious was very close behind with 5 cases. 
*Conjuctivitis, allerg. was listed with 3 cases. 
TABLE 7 
DIAGNOSIS N: cases I COM 
Glaucoma 6 365.9 
Conjunct., infect. 5 372.00 
Conjuct., allerg. 3 372.14 
Inclusion conjunct. 1 77.00 
Iritis 1 364.00 
Pinguecula 1 372.51 
Hordeolum, et. 1 373.11 
Epiphoria 1 375.20 
other mucopurulent conjunc 1 372.03 
Cataract, sec 1 366.50 
Foreign body in conjunct. sac 1 930.10 
Glaucomna, suspect 1 365.00 
Central serous r. 1 362.41 
Diabetic retinop. 1 362.01 
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OBJECTIVE 2.1 : TO DETERMINE IF THE UTILIZATION OF TPAs DIFFERS AS 
A FUNCTION OF THE MODE OF PRACTICE. 
Respondents were asked their mode of practice, total working hours for the 
entire month of November and number of all ocular disease patients seen. 
The following tables and figures illustrate average hours worked per mode of 
practice and average numbers of patients seen per mode of practice. See table 
7 and Figures 7 or 8. 
The average numbers of patients per mode of practice are summarized below. 
*The highest amount of ocular disease patients seen occurred within the 
"group practice plus ophthalmologist" category with an average of 30.67 
patients per practice. 
*Military optometrists averaged 14 patients/month which becomes the 
second highest number of disease cases. 
*Group practice was very close behind with an average of 13 ocular 
disease patients seen per month. 
*Professional setting averaged 11.31 ocular disease patients per month. 
* HMO was very close behind at 11.13. 
*Corporate practice saw the least number of ocular disease patients, with 
an average of 2.6 patients per practice. 
The average number of practice hours per mode of practice is summarized as 
follows: 
*The corporate practice optometrist averaged the highest with 175.54 
hours per practice. 
*The retail setting optometrist averaged 157.04 hours per practice. 
*The professional setting optometrist averaged 153.71 hours per practice . 
* The group practice optometrist averaged 152.93 hours per practice. 
*The optometrists in a "group practice plus opthalmologist" had an 
average of 131.7 hours per practice which is the lowest. 
FIGURE 7: MODE OF PRACTICE VERSUS HOURS/PRACTICE 
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FIGURE 8: MODE OF PRACTICE VERSUS PAT/PRACTICE 
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TABLE 7 
MODE 
PATIENTS/PRACTICE 
AVERAGE MAX MIN 
GRP. + OPTHAL 30.67 47 20 
MILITARY 14.00 14 14 
GRP PRACTICE +00 13.13 89 3 
PROFESSIONAL SETTING 11.31 26 2 
HMO 11.13 20 
RETAIL SETTING 6.70 18 3 
CORPORATE PRACTICE 2.60 6 
HOURS/PRACTICE 
AVERAGE MAX MIN 
CORPORATE PRACTICE 175.54 200 136 
RETAIL SETTING 157.04 220 57 
PROFESSIONAL SETTING 153.71 200 100 
GRP. PRACTICE+ 00 152.93 170 120 
MILITARY 144.00 144 144 
HMO 139.65 130 130 
GRP PRAC + OPTHAL 131.70 145 128 
OPTHALMOLOGIST REFERRAL SOURCES IN THE AREA 
HOURS/PRACTICE 
AVERAGE MAX MIN 
ZERO 165.78 170 126 
1 to 2 148.82 192 57 
3 to 10 152.7 200 100 
11 to 15 175.63 200 155 
16 to 20 128 128 128 
21 to 25 134.5 170 128 
:> 30 137:29 200 120 
PATIENTS[ PRACTICE 
AVERAGE MAX MIN 
ZERO 13 25 1 
1 to 2 6.38 14 1 
3 to 10 10.33 26 
11 to 15 3.4 6 1 
16 to 20 15 15 15 
21 to 25 20 51 6 
> 30 13 25 1 
TABLE 8 
POPULATION 
HOURS/PRACTICE 
AVERAGE MAX MIN 
<5,000 172.00 172 172 
5,000 - 19,999 156.82 220 124 
20,000-39,999 150.46 200 124 
40,000- 69,999 139.31 172 100 
70,000- 149,999 166.45 180 148 
150,000 - 499,999 138.55 192 120 
>500,000 144.61 200 126 
PATIENTS/PRACTICE 
AVERAGE MAX MIN 
<5,000 33.00 25 19 
5,000- 19,999 8.79 26 
20,000 -39,999 10.70 26 
40,000 - 69,999 7.10 16 1 
70,000- 149,999 . 5.38 20 1 
150' 000-499 '999 11.18 21 1 
>500,000 13.17 25 1 
INCOME 
HOURS/PRACTICE 
AVERAGE MAX MIN 
30,000- 39,999 127.98 170 57 
40,000 - 49,999 162.67 180 124 
50,000- 59,999 172.88 220 130 
60,000- 69,999 154.00 200 130 
70,000 - 79,999 166.96 200 134 
80,000- 89,999 141.71 160 120 
100,000 - 124,999 132.13 148 126 
125,000- 149,999 150.00 150 150 
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TABLE 9 
INCOME 
PATIENTS[PRACTICE 
AVERAGE MAX MIN 
30,000-39,999 8.17 15 3 
40,000-49,999 3.40 12 1 
50,000-59,999 6.50 18 1 
60,000-69,999 9.20 26 1 
70,000-79,999 14.14 22 6 
80,000-89,999 12.50 16 8 
100,000-124,999 14.83 25 3 
125,000-149.999 18.50 26 11 
YEARS 
HOURS/PRACTICE 
AVERAGE MAX MIN 
1 to 5 170.01 220 136 
6 to 10 145.28 200 57 
11 to 15 137.93 170 100 
16 to 20 138.00 160 128 
21 to 30 161.45 200 124 
31 + 164.67 172 150 
PATIENTS/PRACTICE 
AVERAGE MAX MIN 
1 to 5 6.47 18 1 
6 to 10 8.50 20 2 
11 to 15 11.35 26 
16 to 20 16.14 47 1 
21 to 30 8.57 26 1 
31 + 16.50 22 11 
IX OBJECTIVE 2.2 :TO DETERMINE IF THE UTILIZATION OF TPAs DIFFERS 
AS A FUNCTION OF THE SIZE OF THE COMMUNITY. 
Respondents were asked the size of their community, practice hours per month, 
and number of ocular disease patients seen in the month of November. 
The average number of patients seen in the month of November was compared 
against the size of the community. A summary of the figures and tables is as 
follows; see table 8 and figures 9 or 10. 
*The optometrists practicing in communities with less than 5,000 
population saw the highest amount of ocular disease cases. They saw 
33 cases per month on the average. 
*The second highest amount of disease seen was in the greater than 
500,000 size community. These optometrists saw 13.17 patients per 
month on the average. 
*The lowest amount of ocular disease cases seen were with the 70,000 to 
149,999 population size. 
The average number of hours per practice in the month of November versus size 
of community is summarized as follows: 
*Optometrists who practice in communities of less than 5,000 
population had the highest number of hours per practice at 172. 
*The optometrists who practice in 150,000-499,999 reported the lowest 
number of hours per practice. 
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FIGURE 10: POPULATION VERSUS PAT/PRACTICE 
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X. OBJECTIVE 2.3: TO DETERMINE IF THE UTILIZATION OF TPAs DIFFERS 
AS A FUNCTION OF THE INCOME OF THE OPTOMETRIST. 
Respondents were asked to estimate net practice income. This information was 
compared against patients per practice and number of practice hours. This is 
illustrated in the following tables and figures. 
The average number of patients per practice as a function of income is 
summarized as follows, see table 8 and 9, figures 11 and 12. 
*Those with a net practice income of $125,000 to $149,999 reported the 
highest average of ocular disease patients. 
*The optometrists with a net practice income of $100,000 to $124,999 
reported the second highest ocular disease patients. 
*The optometrists with a net practice income of $40,000 to $49,999 saw 
the least number of ocular disease patients. 
The average numberof hours per practice versus income are reported as follows: 
*optometrists with incomes of $50,000 to $59,999 had the highest 
average hours of practice. 
*The second highest average of practice hours were those optometrists 
with incomes of $70,000 to $79,999. 
*The optometrists that had incomes of $30,000 to $39,999 had the lowest 
amount of hours of practice. 
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FIGURE 11: INCOME VERSUS HRS./PRACT. 
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XI. OBJECTIVE 2.4: TO DETERMINE IF THE UTILIZATION OF TPAs DIFFERS 
AS A FUNCTION OF THE AVAILABLE REFERRAL SOURCES IN THE 
COMMUNITY. 
Respondents were asked to estimate the number of ophthalmology referral 
sources in their area. The number of ophthalmology referral sources was plotted 
against the average number of patients per practice an average number of 
practice hours. See table 7 and figures 13 or 14. 
The average number of patients per practice seen as a function of 
ophthalmologist referral sources is as follows: 
*The optometrists with 21-25 referral sources had the highest amount of 
ocular disease patients per practice. They saw and average of 20 
patients per practice. 
*The optometrist with 16-20 referral sources saw 15 patients per practice. 
*There is a noticeable difference between optometrists with 11-15 and 1-2 
referral sources as opposed to those with 21-25 . Those with 1-2 and 11-
15 referral sources saw 6.38 and 3.4 patients per practice, respectfully, 
whereas optometrists with 21-25 referral sources saw on the average 20 
patients per practice. 
A summary of the average number of practice hours as a function of 
ophthalmologist referral sources is as follows: 
*Those optometrists with 11-15 referral sources worked the longest hours. 
The average was 175.63. 
*The optometrists with 21-25 referral sources worked an average of 134.5 
hours. This average was very close to those optometrists with referral 
sources of >30. The average practice hours for sources >30 was 137.29. 
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FIGURE 13: OPHTHALMOLOGIST REFERRAL SOURCES IN AREA VERSUS HRS./PRACTICE 
1 80 T • 
1 6 0 IJI------------ ~-----------~ 
I --~-· 
1 4 0 1 -~-~------· 120 
HOURS PERi 00 t 
PRACT. 8 0 T 
6 0 ' T 
4 o r 
20 I 
o Lr -------~-----~-------------~----------~ 
ZERO i-2 3-
1 0 
; 1 -
1 5 
; 6-
20 
NUMBER OF REFFERAL SOURCES 
46 
2;-
25 
> 30 
FIGURE 14: OPHTHALMOLOGIST REFERRAL SOURCES IN AREA VERSUS PAT/PRACTICE 
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XII. OBJECTIVE 2.5 TO DETERMINE IF THE UTILIZATION OF TPAs DIFFERS 
AS A FUNCTION OF THE NUMBER OF YEARS IN OPTOMETRIC PRACTICE. 
Respondents were asked to record the number of years in practice. The following 
is a summary of the tables and figures illustrating the number of years in practice 
versus the number of ocular disease cases seen. The number of years in 
practice was plotted against ocular disease patients per practice and number of 
hours per practice. 
The following is a summary on the average practice hours as a function of years 
in practice, see table 9 and figures 15 or 16. 
*Optometrists practicing 31 +years saw the largest number of ocular 
disease patients (16.5). 
*Optometrists practicing 16-20 years saw the second highest amount 
ocular disease patients (16.14). 
*Optometrists practicing 11-15 years saw an average of 11.35 ocular 
disease patients. 
* Optometrists practicing 1 to 5 years saw the lowest number of ocular 
disease patients (6.47). 
The following is a summary on the average practice hours as a function of years 
of practice: 
*Optometrists practicing 1 to 5 years had the highest number of practice 
hours (170.01 ). 
*Optometrists practicing 6 to 1 0 years had an average of 145.28 hours per 
practice. 
* Optometrists with the lowest number of hours per practice were those 
who had been in practice 11 to 15 years(137.93). 
*The optometrists practicing between 16-20 years had an average of 138 
hours per practice. 
FIGURE 15: YEARS IN PRACTICE VERSUS PATIENTS PER PRACTICE 
18.00 I 
16.00 ~ ·1-----· 
14.00 ~ 
12 .00 t • 
PATIENT PER 10.00 t ~.....-----
PRACT. 8.00 ~- --------
• 6.oo T 
4.00 t 
2.00 
0. 0 0 -1---- ---+--
1 to 5 6 to 10 11 to 1 5 
YEARS IN PRACTICE 
i 6 to 20 31 + 
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DISCUSSION 
RELATIVE FREQUENCY: 
Available alternatives to primary medical care can cut down on the expense of 
an additional visit to a physician, travel and delayed treatment. An expanded role 
for optometry allows optometrists to meet this need as a lower cost alternative to 
medical care.2 With TPA legislation, ocular disease conditions that were 
previously referred to ophthalmologists, are now effectively managed by 
optometrists. As evident in the results of this study, the number of ocular 
disease conditions that are managed by optometrists demonstrates the positive 
effect of TPA utilization on providing services to the public. It also illustrates the 
need for and effectiveness of alternative primary care. As seen in the study, the 
proportion of conjunctivitis (infectious) and glaucoma is 12% and 9.24% 
respectively. (table 1) Approximately, 1 in 10 ocular disease cases will be 
conjunctivitis (infectious) or glaucoma. This is worth noting since there has been 
a high interest within the profession to treat glaucoma and conjunctivitis more 
extensively. (table 7) Future projections of TPA utilization may include an 
increase in prescribing privileges for these disease conditions. 
Also, A comparison between the top seven most prevalent disease conditions 
treated independently (table 4) correlate with the top seven most common 
disease conditions seen. (table 1) Thus, treatment privileges have allowed 
optometrists to effectively manage the majority of ocular disease. 
STANDARD OF CARE 
An optometrist is expected to perform with a level of skill and learning that meets 
certain standards of the profession. This obligation is in accordance with the 
"due care" requirements.10 According to Classe, "As long as the optometrist 
uses the minimum degree of skill and learning expected of a like practitioner 
under the same or similar circumstances, he will not be liable."11 
The standard of care changes as new pharmaceutical agents and information on 
diseases are discovered. Therefore, optometrists must keep abreast with current 
developments in research relative to medication including their adverse 
reactions. In this study, Washington was compared to a similar study in 
Wisconsin. 6 The standard of care in both states is very similar. For example, 
our study indicates a high utilization of four common antibiotics: Gentamicin, 
Tobramycin, Bacitracin and Erythromycin. (table 2) The drug of choice in both 
studies, for infectious conjunctivitis, corneal abrasion, corneal ulcers, foreign 
body and keratoconjunctivitis was the aminoglycosides. For the treatment of 
glaucoma, both studies indicated noticeable agreement in the use of Timolol or 
Betoptic for open angle Glaucoma. In this study, there was little difference 
between the utilization of Betoptic or Timoptic. However, the Wisconsin study 
showed that Timolol was the drug of choice over Betoptic. The reason that 
Timolol is selected over Betoptic could be due to those studies that show 
median intraocular pressure was consistently lower with Timolol as compared to 
Betoptic·12 The drug of choice for allergic conjunctivitis in this study was 
Naphcon A. The Wisconsin study also showed Naphazoline HCL to be the drug 
of choice in the treatment of allergic conjunctivitis. The drug of choice for 
blepharitis was shown to be Bacitracin. This was also the drug of choice in the 
Wisconsin study. The drug of choice in our study for Iritis was Predforte. These 
results were confirmed in the Wisconsin study also. 
REFERRAL 
According to this study, a significant portion of ocular disease cases seen in an 
optometrist's practice includes referral to the appropriate sub-specialty; 
11.06% required referral (table3). Optometrists must be capable of correctly 
diagnosing ocular disease and direct proper referrals. Thus, the cooperative 
interaction between health care providers is an essential part of practice. The 
number of ocular disease patients being referred is an indication of disease not 
treatable by optometrists. This percentage is noticeably lower than the treated 
cases (80%) but greater than cases being co-managed (9.85%). Based upon 
these percentages, optometrists will treat 8 out of 10 patients with ocular disease, 
refer or co-manage 1 in 10 and refer 1 in 10. As seen in this study, TPA 
utilization has allowed optometrists to treat over 80% of ocular disease cases 
thus cutting down on unnecessary referrals. As a result, this reduces travel 
costs, patient fees and delay in treatment. 
MODE OF PRACTICE: 
The amount of ocular disease cases seen within a practice is related to the 
mode of practice. In our study, the "group practice with one ophthalmologist " 
had the highest number of ocular disease patients per practice but the lowest 
number of practice hours (table 7). In comparison, the corporate practice saw the 
lowest amount of ocular disease patients but had the highest amount of practice 
hours. Clearly, the number of ocular disease cases seen per practice is not a 
function of the hours per practice but tends to be a function of the mode of 
practice. This is to say, the group practice with one ophthalmologist would 
expect to see more ocular disease cases than a corporate practice. A similar 
study done on the impact of TPAs on optometric practice by Earmer,9 compared 
mean number of times TPAs were used per week versus mode of practice. The 
results of Farmer's study revealed that the group practice with one 
ophthalmologist had the highest amount of TPAs per week and also the 
corporate practice utilized the least amount of TPAs per week. 
INCOME: 
Optometrist's incomes had a positive relationship with the number of ocular 
disease cases seen (tables 8 and 9). This compares to the study done by 
Farmer9, which revealed that optometrists who used TPAs had a higher income 
than those who did not. According to farmer's study, the higher the mean, as to 
times TPAs were used per week, the higher the income. 
The practice hours had no direct relationship with income. For instance, the 
practices generating incomes of $125,000-149,999 did not have the highest 
amount of practice hours (table 9) but they did see the greatest amount of ocular 
disease patients. An explanation for this could be due to longer hours that new 
optometrists work in their first year but do not generate higher incomes. In 
conclusion, the number of ocular disease patients seen does not correlate with 
greater number of practice hours but does correlate with higher incomes. 
The number of practices with Incomes of $90,000 to 100,000 was not taken into 
consideration because of small sample size. 
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YEARS IN PRACTICE: 
Generally, those optometrists who had been in practice longer saw higher 
numbers of ocular disease patients (table 9). Optometrists that were in practice 
16-20 and 11-15 years saw a larger number of patients, an average of 16. 14 and 
11.35 respectively. According to the study done by Farmer, the 16-20 and 11-15 
year practices had the highest TPA utilization. 
The practices of 21-30 years was not taken into consideration because of small 
sample size. 
POPULATION: 
The communities with a population community size of less than 5,000, saw the 
most ocular disease patients and had the longest practice hours (table 8). An 
explanation is the decreased availability of ophthalmologists in the area. In fact, 
the number of patients seen where there were zero referral sources saw a fairly 
large number of ocular disease patients. ln comparison, in the Farmer study9, 
TPA utilization was also shown to be among the highest in the practices serving 
communities of less than 5,000 population size. This suggests that patients may 
self refer to ophthalmologists when they have a "presence" in a given community. 
The study design differed between the Wisconsin study and this study. In 
Wisconsin, optometrists were asked to rate treatment outcomes objectively. In 
contrast, this study focused on the specific drug of choice and drug utilization as 
a function of disease conditions seen and various profiles of practice. The 
Wisconsin study collected data over an entire year; this study took a sample 
month. The drawbacks of this study was the intensive recording that was 
required, hence the trade off of a shorter sampling time frame. 
Summary 
A. The effects of TPA utilization on the top ten most frequent 
ocular disease conditions are as follows. 
*Infectious conjunctivitis (ICDM 372) had represented 12.12% of all 
disease cases (table 1 ). Findings indicate that 73 out of 80 cases or 91% are 
being managed independently. 
The percentage of cases that were treated and referred was 4% or 3 out of 80 
cases. The number of cases that are not being treated but are referred was 4% 
or 3 out of 80 cases. Five of those cases that were referred could have been 
managed with a change in prescribing privileges. 
The drug of choice for infectious conjunctivitis was gentamicin, Tobrex, and 
erythromycin , in order of preference. 
*Glaucoma (ICDM 365.90) represented 9.24% of all disease cases (table 1 ). 
Findings indicate that 31 out of 61 cases or 50% are being managed 
independently. 
The percentage of cases that were treated and referred was 11.47% or 7 out of 
61 cases. The percentage of glaucoma cases that were co-managed was 
42.62% or 26 out of 61 cases. The percentage of cases that are not being 
treated but are referred was 21.31% or 13 out 61 of cases. Six of those cases 
that were referred could have been independently managed with a change in 
prescribing privileges. 
The drug of choice for Glaucoma was Betoptic, Timoptic, and Betoptic S in 
order of preference. 
• Allergic Conjunctivitis (ICDM 372.14) represented 8.18% of all disease 
cases (table 1 ). Findings indicate that 42 out of 54 cases or 77.77% are being 
managed independently. 
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The percentage of cases that were treated and referred was 5.55% or 3 out of 
54 cases. The percentage of cases that were co-managed was 3. 7% or 2 out 
of 54 cases. The percentage of cases that are not being treated but are 
referred was 3. 7% or 2 out 54 of cases. Three of those cases that were 
referred could have been independently managed with a change in prescribing 
privileges. 
The drug of choice for allergic conjunctivitis was Naphcon A, FML, and 
Dexaceclin, in order of preference. 
• Abrasion (ICDM 918.1) represented 7.42% of all disease cases (table 1 ). 
Findings indicate that 100% or 49 out of 49 cases are being managed 
independently. 
The drug of choice for an abrasion was Tobrex and Genoptic in order of 
preference. 
*Blepharitis (ICDM 373.00) represented 5.91% of all disease cases (table 1 ). 
Findings indicate that 100% or 39 out of 39 cases are being managed 
independently. 
The drug of choice for blepharitis was bacitracin, and Polysporin, and 
erythromycin, in order of preference. 
*Iritis (ICDM 364.00) represented 4.24% of all disease cases (table 1 ). 
Findings indicate that 20 out of 28 cases or 71.42% are being managed 
independently. 
The percentage of cases that were treated and referred was 7.14% or 2 out of 
28 cases. The percentage of cases that were co-managed was 25% or 7 out 
of 28 cases. The percentage of cases that are not being treated but were 
referred was 7.14% or 2 out of 28 cases. One of those cases that were referred 
could have been independently managed with a change in prescribing 
privileges. 
The drug of choice for iritis was Predforte, Econopred, and Maxitrol in order of 
preference. 
*Keratoconjunctivitis(ICDM 370.40) represented 3.48% of all disease cases 
(table 1 ). Findings indicate that 23 out of 23 cases or 100% are being 
managed independently. 
The drug of choice for keratoconjunctivitis was gentamicin and Tobradex in 
order of preference. 
*Pseudophakia(ICDM v43.1) represented 3.48% of all disease cases (table 
1 ). Findings indicate that 7 out of 23 cases or 30.43% are being managed 
i ndepe nde ntly. 
The percentage of cases that were treated and referred was 39.13% or 9 out of 
23 cases. The percentage of cases that were co-managed was 52.17% or 12 
out of 23 cases. The percentage of cases that are not being treated but are 
referred was 8.6% or 2 out of 23 cases. One of those cases that were referred 
could have been managed independently with a change in prescribing 
privileges. 
The drug of choice for pseudophakia was Predforte. 
*Foreign body(ICDM 930.00) represented 3.33% of all disease cases (table 
1 ). Findings indicate that 19 out of 22 cases or 86.36% are being managed 
independently. 
The percentage of cases that were treated and referred was 9.09% or 2 out of 
22 cases. The percentage of cases that are not being treated but are referred 
was 13.63% or 3 out of 22 cases. 
The drug of choice for foreign body is Tobrex and gentamicin, in order of 
preference. 
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*Keratitis(ICDM 370.20) represented 3.18% of all disease cases (table 1 ). 
Findings indicate that 20 out of 21 cases or 95.23% are being managed 
independently. 
The percentage of cases that were co-managed was 4.76% or 1 out of 21 
cases. 
The drug of choice for keratitis is Maxitrol, Polysporin and Genoptic, in order of 
preference. 
B. TPA utilization as a function of the nature of the practice. 
*mode of practice: The number of ocular disease cases seen per practice 
is a function of the mode of a practice. In our study, the "group with one 
ophthalmologist" had the highest number of ocular disease patients per 
practice. The corporate practice saw the lowest amount of ocular disease 
patients per practice. 
*income: Optometrist incomes had a positive relationship with the number of 
ocular disease cases seen. 
*referral: Generally, those optometrists who have a larger number of refferal 
sources saw the most ocular disease patients per practice. 
*years: Generally, those optometrists who had been in practice longer saw 
higher numbers of ocular disease patients. 
*population: The communities with a population community of less than 
5,000 saw the most ocular disease patients. 
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To the optometrists of Washington 
This is a study to determine the scope of therapeutic pharmaceutical practice 
among optometrists in the treatment and management of ocular disease. It 
includes a study of cases that are treated independently, referred and co-
managed. utilizing as a sample those cases seen in November, 1992. Your 
participation in this study will help establish solid data illustrating the 
effectiveness of optometrists using TPA's in an actual practice setting. This 
information will prove helpful to other states, making the "case" for prescribing 
privileges. 
INSTRUCTIONS: 
1. Please take the time to fill out part one of the questionnaire; 
some questions can only be answered. once the month of 
November comes to a close. 
2. Complete part two each time you treat or refer a patient for an 
ocular disease. 
3. BEGIN part two on NOVEMBER 1st and continue through 
the last day of practice in November. 
5. Please return data sheets in the enclosed postage free 
envelope EARLY in DECEMBER. 
Thank-you for participating, your responses will contribute to optometry's 
goal to expand the scope of practice and help other states succeed in their 
legislative efforts. Please be assured that anonymity will be protected in the 
study. Return envelopes will be opened by a third party with the data sheets 
alone being analyzed in the study. 
PART ONE 
1. What best describes your type of practice? 
( 1 Private practice/professional setting 
[ ] Private practice/retail setting 
[ ] Group practice with 1 + optometrists 
[ 1 Group practice with 1 + ophthalmologists 
( ] Chain or corporate practice 
( ] HMO or group maintenance practice 
[ ] Military 
2. Population estimate of city you practice in? 
[ ] less than 5, 000 
[ 1 5,000 to 19,999 
[ ] 20,000 to 39,999 
[ 1 40,000 to 69,999 
[ ] 70,000 to 149,999 
[ 1 150,000 to 499,999 
[ ] 500,000 or more 
3. How many years have you been in practice? 
__ number of years in practice 
4. Number of hours in practice for the month of November 
number of hours 
5. What category best describes your net practice personal income? 
[ ] less than $30,000 
[ 1 30,000 to 39,999 
[ ] 40,000 to 49,999 
[ ] 50,000 to 59,999 
[ 1 60,000 to 69,999 
( ] 70,000 to 79,999 
[ ] 80,000 to 89,999 
[ 1 90,000 to 99,999 
[ ] 100,000 to 124,999 
{ 1 125,000 to 149,999 
( ] 150,000 or more 
6. What best describes your area of specialty/expertise? 
( ] vision therapy 
[ ] contact lenses 
[ ] sports vision 
[ 1 family practice 
[ 1 ocular disease 
( ] pediatrics/child care 
7. What is the number of patients in the month of November that you independently treated with TPA's 
who were later referred to an ophthalmologist because of complications. 
__ number of patients referred 
8. The number of ophthalmologist referral sources in your area? 
_zero 
_ 1-2 
3-10 
_ 11-15 
_ 16-20 
21-25 
- 26-30 
_ greater than 30 
TPA Utilization Study 
' 
Case number Diagnosis •antibiotic Drug used Case Case Case If case referred or co-managed 
-steroid including dosage referred to referred co-managed could it have been treated 
•mydriatic ophthalm. to independently with broader 
-decongestant other optometric prescribing 
Please •nonsteroidal specialist privileges? 
use 
-
anti-inflammatory 
~ 
diagnostic •anti-fungal 
codes on •anti-viral please please please please 
attached •other enter enter enter enter 
sheet select from above enter drug name and dosage yes or no yes or no specialty yes or no 
1 
-i 2 
3 
4 
5 
6 
7 
8 
9 i 
- ----
10 I I 
11 i 
12 
13 
14 
15 
16 
17 
18 
-
19 
20 
-
21 
22 
- -1 
' . 
-23 
24 
25 l 
DIAGNOSIS 
General ~ Retina 
Atherosclerosis 440.0 Aphakia 379.31 Medullated nerve 743.57 
Diabetes 250.5 Cataract 366.9 Melanoma 190.5 
Headaches, Migraine 346.0 Cararact, sec. 366.50 Neoplasm, benign 224.5 
Headaches, tension 307.8 Pseudophakia V43.1 Neoplasm, malign. 190.5 
Head pain 784.0 Neovascularization 362.16 
Myasthenia gravis 358.0 ug Occlusion, artery 362.31 
Neoplasm, benign 229.0 Abcess 373.13 Occlusion, vein 362.35 
Neoplasm, malignant 199.0 Bell's palsy 351.0 Optic neuropathy 377.39 
Sinusitis, acute 461.0 Black eye 921.0 Optic nerve atrophy 377.10 
Thyroid 246.0 Blepharitis 373.00 Papilledema 377.00 
Blepharospasm 333.81 Retinitis Pigment. 362.74 
Anterior Chamber Burn 940.1 Retinoblastoma 190.5 
Adie's snydrome 379.46 Carcinoma 232.1 Retrobulbar neuro. 377.32 
Anisocoria 379.41 Cellulitis, orbit. 376.01 Retrolental fibre. 362.21 
Argyii-Robertson 094.89 Chalazion 373.2 Scotoma 368.4 
Coloboma, iris 743.46 Cilia, absence 743.63 Thrombosis 362.30 
Glaucoma 365.9 Concretion 374.56 
Glaucoma, suspect 365.00 Contusion 921.9 Q1b.ftl: 
Horner syndrome 337.9 Cyst 374.84 
Hyphema 364.41 Dacryoadenitis 375.00 
Hypopyon 364.05 Dacryocystitis 375.30 
Iritis (uveitis} 364.00 Dendritic keratit. 054.42 
Myotonic pupil 379.46 Dermatitis contac.692.9 
Pan uveitis 360.12 Dermatitis allerg 373.32 
Rubeosis iridis 364.42 Ectropion 37 4.1 1 
Synechiae 364.70 Entropion 374.01 
Epiphoria 375.20 
Cornea Exophthalmos 376.30 
Abrasion 918.1 Hordeolum, ext. 373.11 
Bullous Keratopath 371.23 Hordeolum, int. 373.12 
Burn 940.4 Inflammation 373.9 
Dry eye syndrome 375.15 Laceration 870.0 
Dystropy 371.50 Lac. duct obst. 375.56 
Erosion 371.42 Meibomitis 373.12 
Edema 371.20 Molluscum contag078.0 
Foreign body 930.0 Ptosis 374.30 
Herpes Simplex 054.40 Trachoma 076.9 
Herpes Zoster 053.20 Trichiasis 374.05 
Keratitis 370.20 Verruca 078.1 
Keratoconjuctivitis 370.40 Xanthelasma 374.51 
Keratoconus 371.60 
Krugenberg's spin 371.13 Vitreous 
Laceration 871.4 Asteroid Hyalitis 379.22 
Opacity 371.00 Detachment 379.21 
Penetration wound 871.7 Hemorrhage 379.23 
transplant,cornea V42.5 Opacities 379.24 
ulcer 370.00 
QonjuQtiva I sQjera .&!.ir1g 
Cellulitis, orbit. 376.01 Artherosclerotic r.362.13 
Conjuct., infect. 372.00 Color deficiency 368.5 
Conjuct., allerg. 372.14 Choroiditis 363.20 
Cyst 372.75 Csytoid mac. ed. 362.53 
Edema 372.73 Central serous r. 362.41 
Endophthalmitis 376.50 Detachment (tear)361 .9 
Episcleritis 379.00 Diabetic retinop. 362.01 
Foreign body 930.1 Drusen 362.57 
Hemangioma 228.00 Embolirsm 362.33 
Laceration 871.4 Hemorhage 362.81 
Pinguecula 372.51 Hemianopsia 368.47 
Pterygium 372.40 Hypertensive r. 362.1 1 
Scleritis 379.00 Ischemia 362.84 
Subcong. hernorrhag. 372.72 Macular degen. 362.50 
